FDA approves Boehringer Ingelheim’s HERNEXEOS® (zongertinib) as the first oral targeted therapy for treatment-naïve adults with HER2-mutant advanced NSCLC. Phase Ib data show 76% ORR; confirmatory Phase III Beamion LUNG-2 (NCT06151574) ongoing.
Written By: Pharmacally Medical News Desk
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) for adult patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.
This accelerated approval marks the first oral targeted therapy for treatment-naïve patients in this population, building on its prior approval in August 2025 for previously treated cases.
Strong Efficacy in Treatment-Naïve Patients
Approval based on data from a Phase Ib Beamion LUNG-1 trial cohort (N=72 treatment-naïve patients, NCT04886804), showing an objective response rate (ORR) of 76% including 11% complete responses and 65% partial responses.
Notably, 64% of responders maintained a duration of response (DOR) of at least 6 months. Continued approval awaits confirmatory data from the ongoing Phase III Beamion LUNG-2 trial (NCT06151574), now enrolling patients for first-line evaluation.
“Zongertinib is setting a new standard as the first targeted therapy for treatment-naïve patients with HER2-mutant advanced NSCLC, with demonstrated efficacy, a manageable safety profile, and once-daily oral administration,” said Dr. John Heymach, MD, PhD, coordinating investigator for Beamion LUNG-1 and chair of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. “Now these patients finally have a targeted treatment option immediately following HER2 mutation identification.”
Addressing a High-Unmet Need in HER2-Mutant NSCLC
HER2 (ERBB2) mutations drive 2-4% of NSCLC cases, linking to poor prognosis and elevated brain metastasis risk. These alterations fuel uncontrolled cell proliferation, evading cell death and promoting tumor spread. Lung cancer remains the leading cancer killer, with NSCLC often diagnosed late and a 5-year survival under 10% for advanced stages.
“With HERNEXEOS now approved as an initial treatment option, we are transforming care for this rare, aggressive cancer,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “This underscores our focus on personalized care and accelerating innovation.”
Danielle Hicks, Chief Patient Officer of GO2 for Lung Cancer, added: “Half of these patients don’t respond to standard care, making biomarker-driven options vital. Understanding HER2 mutations unlocks personalized treatments.”
Manageable Safety and Key Designations
In a pooled safety set (N=292 HER2-mutant NSCLC patients), zongertinib showed consistency across naïve and pretreated groups. Dose discontinuations due to adverse events occurred in 6% of naïve patients. Common adverse reactions (>20%) included diarrhea (54%), rash (28%), hepatotoxicity (27%), fatigue (25%), nausea (23%), musculoskeletal pain (21%), and upper respiratory tract infection (20%).
The FDA previously granted zongertinib Breakthrough Therapy Designation for first line use and a Commissioner’s National Priority Voucher, highlighting its potential.
About HERNEXEOS and Ongoing Trials
HERNEXEOS is an irreversible tyrosine kinase inhibitor (TKI) selectively targeting mutant HER2 while sparing wild-type EGFR to reduce toxicities. Eligibility requires next-generation sequencing for HER2 mutations.
Boehringer advances evaluation in Beamion LUNG-2 (first-line advanced NSCLC; NCT06151574) and Beamion LUNG-3 (adjuvant in early-stage resectable NSCLC Stage II-IIIB; NCT07195695).
Reference
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option, 26 February 2026, https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/fda-approves-hernexeos-first-line-lung-cancer
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People with Different Types of Advanced Cancer (Solid Tumours with Changes in the HER2 Gene), ClinicalTrials.gov ID NCT04886804, https://clinicaltrials.gov/study/NCT04886804
FDA Grants Second Approval under the National Priority Voucher Pilot Program, 26 February 2026, https://www.fda.gov/news-events/press-announcements/fda-grants-second-approval-under-national-priority-voucher-pilot-program